DSIJ Mindshare

IPO Analysis: Jupiter Life Line Hospitals Limited
Mandar Wagh
/ Categories: Trending, IPO, IPO Analysis

IPO Analysis: Jupiter Life Line Hospitals Limited

IPO Rating: Apply for long-term

About the Issue 

Established in 2007, Jupiter Life Line Hospitals Limited has emerged as a prominent healthcare institution, specialising in multiple medical disciplines and offering tertiary and quaternary healthcare services across the Mumbai Metropolitan Area (MMR) and the western region of India. 

The company is gearing up to launch its Initial Public Offering (IPO) for equity shares, each having a face value of Rs 10. The IPO price range is set between Rs 695 and Rs 735 per equity share, resulting in a total issue size of Rs 869.08 crore at the upper price band. 

The IPO is scheduled to commence on September 6, 2023, and will conclude on September 8, 2023. The anticipated listing on the exchange is set for September 18, 2023. The market lot size for the IPO is 20 shares, with the option to apply for multiples of this lot. Individual retail investors have the opportunity to apply for a maximum of 13 lots, equivalent to 260 shares or a total investment of Rs 191,100, assuming the upper price band. 

IPO Details
IPO Opening Date  September 6, 2023
IPO Closing Date  September 8, 2023
Issue Type  Book Built Issue IPO
Face Value Rs 10 per equity share
IPO Price  Rs 695 to Rs 735 per equity share
Min Order Quantity  20 Shares
Post Issue implied Market Cap Rs 4,819.1 crore
Listing At  BSE, NSE
Issue Size  11,824,163 shares of FV Rs 10*
(Aggregating up to Rs 869.08 Cr)*
Fresh Issue 7,374,163 shares of FV Rs 10*
(Aggregating up to Rs 542.00 Cr)*
Offer for Sale 4,450,000 shares of FV Rs 10*
(Aggregating up to Rs 327.08 Cr) *
QIB Shares Offered  20.53% of the Offer
Retail Shares Offered  34.77% of the Offer
NII (HNI) Shares Offered 14.90% of the Offer
*At Upper Price Band  

 

Objects of the Issue 

The company plans to allocate the net proceeds raised from the issue for the following purposes: 

1. Repayment or pre-payment, either in full or in part, of loans obtained from banks by the company and its material subsidiary. 

2. Meeting general corporate requirements and expenses. 

Promoter holding 

The promoters currently hold a pre-issue shareholding stake of 40.69 per cent in the company. 

Company profile 

The inaugural Jupiter Hospital is strategically located near the pivotal Eastern Express Highway in Thane, ensuring convenient access and connectivity for patients from Thane and beyond. Expanding its reach, Jupiter Hospital ventured into Pune in 2017, and subsequently, in 2020, extended its multi-speciality tertiary and quaternary care services to Indore, Madhya Pradesh, with the establishment of Vishesh Jupiter Hospital. As of today, the hospital network boasts over 1100 beds across three cities. These hospitals employ a Greenfield strategy to comprehensively address the healthcare requirements of their patients. 

Specialised departments at the hospital are supported by highly skilled and experienced doctors, as well as a dedicated team of healthcare professionals who are experts in their respective fields. The hospital's specialities span a broad spectrum, encompassing fields such as bariatric surgery, cardiac surgery, cardiology, dermatology, gastroenterology, nephrology, neurology, neurosurgery, gynaecology, urology, and more, providing comprehensive healthcare solutions. 

Jupiter Hospital has achieved a significant milestone by joining the ranks of a select group of medical facilities offering computer-assisted neuro rehab centres and knee replacements performed through robotic surgery. Furthermore, the hospital is presently in the stages of constructing a multi-speciality healthcare facility in Dombivli, Maharashtra. This facility has been designed to accommodate more than 500 beds. 

Financials

Rs (in crore) FY20 FY21 FY22 FY23
Sales 463 486 733 893
Operating Profit 84 67 153 201
Other Income 0 4 4 8
EBITDA 84 71 157 209
Interest -26 -39 -44 -42
Depreciation -26 -31 -36 -39
Profit before tax (PBT) 32 1 77 128
Tax -2 -3 -26 -55
Net Profit 30 -2 51 73

 

Outlook and Valuation 

The COVID-19 pandemic highlighted the critical need for fundamental medical facilities throughout the country, subsequently elevating the significance of the industry. The healthcare industry is currently experiencing and is poised to continue undergoing substantial growth and transformation in the years ahead. Jupiter Life Line Hospitals is gaining prominence due to its position as one of the leading providers of cutting-edge and advanced healthcare services, complemented by state-of-the-art diagnostic capabilities. 

If we calculate the PE ratio by attributing FY23 earnings to the post-IPO fully diluted paid-up equity capital of the company, the resulting PE ratio stands at 66.10. To provide a comparative perspective, the offer document highlights Apollo Hospitals, Krishna Institute of Medical Sciences, Narayana Hrudayalaya, Fortis Healthcare, and Max Healthcare as their listed peers. It's important to note that while these companies are trading at PE ratios of 107, 47, 30, 43, and 49, respectively, they may not be directly comparable on a strictly like-for-like basis given variations in their business models, operations, and market dynamics. 

The issue is priced with a P/BV ratio of 11.41, calculated using its Net Asset Value (NAV) of Rs 64.39 as of March 31, 2023. At the upper price cap, it is priced at a P/BV ratio of 4.68, considering its post-IPO NAV of Rs 156.93 per share. 

When considering the company's growth prospects, it's noteworthy that the company is actively expanding its presence in the Western regions as part of its strategic expansion efforts. It has reported impressive growth in both its revenue and net profit over the past few years. It boasts a robust RoE and RoCE of 20 per cent, underscoring its impressive profitability. 

After the IPO, the company will transition into a debt-free entity, which will result in increased cash generation and savings in finance costs. Hence, we recommend investors to subscribe the issue with a long-term perspective. 

 

Previous Article Rs 1,275 crore order book: This multibagger aerospace & defence company receives order worth Rs 123.3 crore from the Ministry of Defence!
Next Article 300 per cent returns in this multibagger stock; Board announces bonus shares and stock split!
Print
940 Rate this article:
4.7
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR